Knowledge, Attitude and Practices of Physicians in Pakistan towards Onco-Hypertension: A Cross-sectional Study
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Onco-hypertension, the interplay between cancer and hypertension, is an emerging specialty highlighting the bidirectional relationship between carcinogenesis, anticancer therapies, and blood pressure regulation. In Pakistan, data on physicians’ awareness and management of onco-hypertension are limited, yet critical given the rising global burden of cancer (24.5 million new cases; 9.6 million deaths in 2017) and hypertension (7.6 million annual deaths) worldwide. Methods A cross-sectional survey was conducted from May to October 2023 among physicians in oncology, internal medicine, cardiology, and allied specialties across tertiary hospitals, private clinics, and teaching institutions in Pakistan. A self-structured questionnaire, covering sociodemographic, knowledge, attitudes, and clinical practices, was distributed online and in person. Descriptive statistics summarized respondent characteristics, and inferential tests (t-tests, ANOVA) examined associations (p < 0.05). Results Mean respondent age was 37.5 ± 7.8 years; 58% male. Specialty distribution: internal medicine (45%), oncology (16%), cardiology (17%), nephrology (8%), pulmonology (13%), and others (1%). Nearly half (49%) rated their onco-hypertension knowledge as “average,” and 62% reported challenges managing hypertensive cancer patients. Key perceived causes in previously normotensive patients were anxiety (48%) and corticosteroid use (40%). Sixty-three percent sometimes adjusted antihypertensive regimens based on cancer therapies, and 80% endorsed the necessity of interdisciplinary coordination for optimal management. Conclusion Pakistani physicians demonstrate moderate understanding of onco-hypertension with prevalent management challenges. Findings underscore the need for targeted educational initiatives, validated clinical guidelines, and structured interdisciplinary collaboration to improve cardiovascular outcomes in cancer care.